Living watchpoints for regulatory events that longevity marketers may overread, misread or quote without context.
Last checked: Jun 27, 2026
Regulatory events are signals to watch, not proof that a product or intervention is approved for longevity. The July 23-24, 2026 FDA peptide meeting is a compounding-review event, not approval for anti-aging claims.
| Date | Event | Compounds | Status | Source |
|---|---|---|---|---|
| Jul 23, 2026 America/New_York | FDA Pharmacy Compounding Advisory Committee peptide review This is not FDA approval for anti-aging, fitness, recovery or OTC use. It is a compounding-review event for specified uses. Related tracker → | BPC-157, KPV, TB-500, MOTs-C, Emideltide / DSIP, Semax, Epitalon | Upcoming | FDA |
This FDA Pharmacy Compounding Advisory Committee meeting reviews specified compounding questions. Internet claims and FDA-reviewed uses are not the same thing, and review for one use does not validate broader recovery, fitness, anti-aging or biohacking claims.
Internet claim
BPC-157 heals tendons and gym injuries.
FDA-reviewed use
BPC-157: ulcerative colitis.
Why the mismatch matters
A regulatory review for one specified use does not validate broader anti-aging, recovery, performance or consumer claims.
No strong human evidence shows that BPC-157 heals tendon or ligament injuries. Most support is animal, cell or mechanism-based, and internet recovery claims should not be treated as proven clinical benefit.
TB-500 injury-recovery claims are not supported by strong human clinical evidence. The claim often relies on extrapolation from thymosin beta-4 biology and should be treated as unproven.
Semax has been discussed in non-US medical and research contexts, but that does not prove it improves cognition in healthy people. Healthy-user nootropic claims remain unproven.
Epitalon is not proven to extend human lifespan. Longevity claims rely on early or indirect evidence and should not be treated as established anti-aging medicine.
MOTS-c is biologically interesting, but human metabolism and longevity claims remain unproven. Do not treat mitochondrial mechanism as clinical proof.